While sales of the popular vaccine Prevnar fell short, Pfizer still reported better-than-expected revenue thanks to strong sales from new treatments.
The New York City-based drugmaker's second quarter revenue increased 11 percent year over year to $13.2 billion.
Prevnar, a vaccine for pneumococcal diseases, saw a decline in sales posting $1.26 billion, compared to the $1.58 billion analysts predicted, according to Bloomberg.
Sales of Ibrance — Pfizer's new breast cancer drug — more than tripled to hit $514 million, surpassing analysts' estimate of $498 million.
Pfizer's new arthritis pill Xeljanz posted 217 million in sales, beating its $199 million projection.
Pfizer reported total earnings of $2.02 billion, or 33 cents a share, a decrease from the $2.63 billion, or 42 cents per share, the company recorded for the second quarter of 2015.
More articles on the drug market:
Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan's generic pharma for $40.5 billion
MIT researchers create programmable device to produce biologics on the spot